Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01012895 · ClinicalTrials.gov registry record · Phase 2
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
NCT01012895 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 215 participants.
The verdict
NCT01012895, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether BMS-650032 and BMS-790052 in combination alone, together with Ribavirin, or together with Interferon and Ribavirin are effective in the treatment of Hepatitis C in patients who have not responded to prior therapy.
Interventions
- DRUG BMS-790052
- DRUG BMS-650032
- DRUG Pegylated-interferon alfa-2a
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01012895
The ClinicalTrials.gov registry entry for NCT01012895 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BMS-790052 is the first listed.
NCT01012895 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01012895 about?
NCT01012895 is a clinical study titled "Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care". The purpose of this study is to determine whether BMS-650032 and BMS-790052 in combination alone, together with Ribavirin, or together with Interferon and Ribavirin are effective in the treatment of Hepatitis C in patients who have not responded to prior therapy.
What is the current status of trial NCT01012895?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2009-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01012895?
The interventions under investigation include: BMS-790052 (DRUG), BMS-650032 (DRUG), Pegylated-interferon alfa-2a (DRUG).
Who is sponsoring clinical trial NCT01012895?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.